DIVISLAB

What Divi's Laboratories promised, and what happened

Every commitment management made on a call, tracked from the quarter it was made — reaffirmed, revised, diluted or quietly dropped.

Guidance record · Q1 FY27

what the last two calls moved 19 tracked 3 delivered 4 missed 12 open
  • Kakinada Phase 1 Commercial Start delivered said Q4 FY24 Promised: Around Q3 FY25 Q1 FY27: Already achieved.
  • Contrast Media Volume Growth missed said Q2 FY25 Promised: 20-30% YoY increase Q1 FY27: Promise remains missed. New updates focus on specific contract commercialization rather than overall volume growth targets.
  • CS Long-Term Agreement Commercialization delayed said Q4 FY25 Promised: Revenue impact by Q3 CY2026 / Q4 CY2026 or January 2027 Q1 FY27: Management confirms readiness for regulatory submissions but commercialization remains contingent on approvals, consistent with the previously delayed timeline of 2027.

The rest of the ledger

Above is what the last two calls moved. Pro opens all 19 tracked commitments for Divi's Laboratories — every quarter's revision, the source quote behind each one, and the topics management has stopped answering.

See what Pro opens